Allergan Archives

Home Allergan

Latest Posts

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer's disease. A year ago, Allergan signed a massive deal of up…

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market…

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 18 Apr 2017

Two Big Pharma Players Team up to Take Over the NASH Space

Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis' FXR agonist for NASH. After Allergan snapped up Tobira's cenicriviroc (CVC) last year in…

April 18, 2017 - 3 minutesmins - By Melanie De Almeida

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency…

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016…

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

heptares allergan neurological alzheimer gpcr

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer's, to Allergan for up to €3Bn. A good way for Allergan to 'get over' yesterday's failed…

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

biosimilar war neulasta herceptin avastin rituxan1

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen's victims... Neulasta (pegfilgrastim) has been submitted through Novartis'…

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 23 Nov 2015

Finally, Pfizer acquires Botox-maker Allergan for €150Bn to move to tax-friendly Ireland!

The Rumor became more and more tangleon what is now the biggest Pharma deal ever. The Rumor was pumped up by reports from Bloomberg and CNBC, saying the deal could…

November 23, 2015 - 1 minutemin - By Philip Hemme

News and Trends 29 Oct 2015

To beat J&J, Pfizer attempts a New Merger…Guess who’s the Target this Time?!

Mergers & acquisitions (or M&A in short) have ruled the world of Pharma for a while and the company which seems to be the most hungry this year is Pfizer! After it failed…

October 29, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 25 Sep 2015

Roche’s patent halts an Amgen biosimilar debut

Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite smashing the phase III trials, the Amgen-Allergan partnership still has…

September 25, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2014

Will New Actavis-Allergan Entity Lead to Be in the World Top 10 Drugmakers Companies?

The US pharmaceutical company Allergan, known for their Botox, agreed an Actavis bid of 53 billion euros, they permanently passed up the proposition of Valeant Pharmaceuticals International and the activist…

November 24, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 28 Jul 2015

Allergan Continues its Serial Acquisitions to be a Giant Drugmaker

With Allergan's absorption by Actavis last year, we ask ourselves, will the newly formed company enter the World's Top Ten drugmaker companies worldwide? And it has been very active indeed, expanding its…

July 28, 2015 - 3 minutesmins - By Philip Hemme

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering